- Bay Area Times
- Posts
- DeepSeek R2 rumored 98%+ cheaper than GPT-4o, trained on Huawei chips
DeepSeek R2 rumored 98%+ cheaper than GPT-4o, trained on Huawei chips
Bay Area Times
April 28, 2025
Brought to you by:
Top stories today:
- DeepSeek R2 rumored 98%+ cheaper than GPT-4o
- Elon’s XAI Holdings said to raise $20B at $120B+ valuation
- Huawei said to have developed Ascend 910D to rival NVIDIA’s AI chips
- Deel sues Rippling for defamation as rivalry escalates
- Neuralink’s ALS patient shares experience regaining communication
0. Data and calendar
All values as of 6 AM ET / 3 AM PT, other than S&P500 and NASDAQ close (4 PM ET / 1 PM PT).
All times are ET.
Listen to our AI-generated podcast summarizing today’s newsletter (beware of hallucinations):
1. DeepSeek R2 rumored 98%+ cheaper than GPT-4o, trained on Huawei chips
1.2T parameter size, with 78B active parameters using a hybrid Mixture of Experts (MoE) architecture.
89.8% scores on the C-Eval 2.0 benchmark.
92.4% scores on COCO for vision capabilities.
Achieved 82% utilization of Huawei’s Ascend 910B AI chip cluster.
TBD: the exact release date.
Jan.: DeepSeek disrupted the AI market with its R1 reasoning model release.
Over 365 million people worldwide suffer from osteoarthritis and there's still no cure, just painkillers and ice packs.
Cytonics’ CYT-108 is a lab-tweaked version of a natural protein (A2M) that blocks the enzymes that eat away at cartilage.
Backed by NIH grants and over 6,000 shareholders, Cytonics is now letting the public invest in its next clinical trial phase.
It’s a shot at finally treating the root cause of joint pain, not just managing it.
*Sponsored by Cytonics ($50,000 contracted). Prospective investors should review the offering materials for details, including all risk factors, before making an investment decision. Any investment involves significant risks, including the potential loss of the total investment. This advertisement is not an offer to sell or a solicitation of an offer to buy securities. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. Please read the offering circular before investing in Cytonics.
3. Elon’s XAI Holdings said to raise $20B at $120B+ valuation
Representational image generated using xAI’s Grok.